Literature DB >> 9875747

Double patch closure of ventricular septal defect with increased pulmonary vascular resistance.

W M Novick1, A T Gurbuz, D C Watson, V V Lazorishinets, A N Perepeka, I Malcic, B Marinovic, B S Alpert, T G DiSessa.   

Abstract

BACKGROUND: Closure of a large ventricular septal defect (VSD) in children with elevated pulmonary vascular resistance is associated with significant morbidity and mortality. Pulmonary hypertensive episodes continue to be a major cause of postoperative morbidity and mortality. We designed a fenestrated flap valve double VSD patch in an effort to decrease the morbidity and mortality associated with the closure of a large VSD with elevated pulmonary vascular resistance.
METHODS: Eighteen children (mean age, 5.7 years) with a large VSD and elevated pulmonary vascular resistance (mean, 11.4 Wood units) underwent double patch VSD closure using moderately hypothermic cardiopulmonary bypass and cardioplegic arrest. The routine VSD patch was fenestrated (4 to 6 mm) and on the left ventricular side of the patch, a second, smaller patch was attached to the fenestration along its superior margin before closure of the VSD.
RESULTS: All children survived operation and were weaned from inotropic and ventilator support within 48 hours postoperatively. Postoperative pulmonary artery pressures were significantly lower than preoperative values. One child died 9 months postoperatively.
CONCLUSIONS: Closure of a large VSD in children with elevated pulmonary vascular resistance can be performed with low morbidity and mortality when a flap valve double VSD patch is used.

Entities:  

Mesh:

Year:  1998        PMID: 9875747     DOI: 10.1016/s0003-4975(98)00956-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension.

Authors:  Sachin Talwar; Shiv Kumar Choudhary; Sanket Garg; Anita Saxena; Sivasubramanian Ramakrishnan; Shyam Sunder Kothari; Rajnish Juneja; Balram Airan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-08

2.  Midterm results of "treat and repair" for adults with non-restrictive ventricular septal defect and severe pulmonary hypertension.

Authors:  Zhenlei Hu; Bo Xie; Xinming Zhai; Jidong Liu; Jianmin Gu; Xudong Wang; Hui Zheng; Song Xue
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 3.  Surgical strategies for patients with congenital heart disease and severe pulmonary hypertension in low/middle-income countries.

Authors:  Sachin Talwar; Vikas Kumar Keshri; Shiv Kumar Choudhary; Saurabh Kumar Gupta; Sivasubramanian Ramakrishnan; Rajnish Juneja; Anita Saxena; Shyam Sunder Kothari; Balram Airan
Journal:  Heart Asia       Date:  2015-10-09

Review 4.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

5.  Unidirectional ventricular septal valved patch for repair of late presenting ventricular septal defect with aortopulmonary window.

Authors:  Neeti Makhija; Jitin Narula; Vikas Kumar Keshri; Saurabh Kumar Gupta; Sachin Talwar
Journal:  Ann Pediatr Cardiol       Date:  2016 Jan-Apr

6.  Unidirectional valved patches for closure of septal defects in patients with severe pulmonary hypertension.

Authors:  Sachin Talwar; Shiv Kumar Choudhary; Anita Saxena; Shyam Sunder Kothari; Rajnish Juneja; Balram Airan
Journal:  Ann Pediatr Cardiol       Date:  2008-07

7.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.